0
Your cart

Your cart is empty

Browse All Departments
  • All Departments
Price
  • R2,500 - R5,000 (2)
  • -
Status
Brand

Showing 1 - 2 of 2 matches in All Departments

Adjuvant Therapies and Markers of Post-Surgical Minimal Residual Disease II - Adjuvant Therapies of the Various Primary Tumors... Adjuvant Therapies and Markers of Post-Surgical Minimal Residual Disease II - Adjuvant Therapies of the Various Primary Tumors (Paperback, Softcover reprint of the original 1st ed. 1979)
Gianni Bonadonna, G. Mathe, S. E. Salmon
R2,721 Discovery Miles 27 210 Ships in 10 - 17 working days

A prospective randomized clinical trial of treatment with vincristine, cyclophosphamide, methotrexate and 5-fluorouracil after conventional curative treatment for stage II breast cancer is described. The results at 2 years are recorded together with details of toxicity. Future plans are discussed briefly. Acknowledgement We wish to acknowledge the participation of all the collaborators in this study, the co-ordinator Dr. ERICA MANSBACHER and the support of Action Cancer in Belfast. References 1. Ahmann, D. L. , O'Connell, M. J. , Hahn, R. G. , Bisel, H. F. , Lee, R. A. , Edmonson, J. H. : An evaluation of early or delayed adjuvant chemotherapy in premenopause1 patients with advanced breast cancer undergoing oophorectomy. New Engl. J. Med. 297, 356-360 (1977) 2. Ahmann, D. L. , Scanlon, P. W. , Bisel, H. F. , Edmonson, J. H. , Frytak, S. , Payne, W. S. , O'Fallon, J. R. , Hahn, R. J. , Ingle, J. N. , O'Connell, M. J. , Rubin, J. : Repeated adjuvant chemotherapy with Phenyl-alanine mustard, or 5-Fluorouracil, Cyclophosphamide and Prednisone with or without radiation after mastectomy for breast cancer. Lancet 1978//, 893-896 3. Bonadonna, G. , Rossi, A. , Valagussa, P. , Banfi, A. , Veronesi, U. : The CMF program for operable breast cancer with positive axillary nodes. Cancer 39, 2904-2915 (1977) 4. Edelstyn, G. A. , Bates, T. S. , Brinkley, D. , Macrae, K. D. , Spittle, M. , Wheeler, T. : Comparison of 5-day, I-day and 2-day cyclical combination chemotherapy in advanced breast cancer.

Adjuvant Therapies and Markers of Post-Surgical Minimal Residual Disease I - Markers and General Problems of Cancer Adjuvant... Adjuvant Therapies and Markers of Post-Surgical Minimal Residual Disease I - Markers and General Problems of Cancer Adjuvant Therapies (Paperback, Softcover reprint of the original 1st ed. 1979)
Gianni Bonadonna, G. Mathe, S. E. Salmon
R2,647 Discovery Miles 26 470 Ships in 10 - 17 working days

P. Denoix and G. Mathe Approximately 70% of cancer patients relapse after surgery before the 5th year and, in most cases, for example in breast carcinoma, they relapse still later up to the 20th year. For some considerable time, the strategy of cancer treatment has been limited to the sophistication of surgery-radiotherapy combinations that maximally decreased the incidence of local and regional relapses in sites that were within their reach. Today, the practice of clinical oncology is unthinkable without the active participation of the medical oncologist. He is the "third man" of the clinical oncology team, and he has recently focused attention on the fact that most relapses arise from distant metastases due to the proliferation of cells seeded there after having left the primary tumor site at the time of operation and, hence, are inaccessible to any form oflocal and/or regional treatment. On this evidence, medical oncologists have proposed the application of medical treatments for disseminated minimal residual disease (MRD). They have two available means: chemother apy and immunotherapy. Medical oncologists in general can be divided into three groups: chemotherapists, immunotherapists, and chemoimmunotherapists. The pure chemotherapists, who had already cured some malignant neoplasias such as Hodgkin's disease, acute lymphoid leukemia, placental choriocarcinoma, and Wilms' tumor, thought they might have the means of attacking the residual disease of common cancers."

Free Delivery
Pinterest Twitter Facebook Google+
You may like...
The Phenomenology of the Noema
J. J. Drummond, Lester Embree Hardcover R2,790 Discovery Miles 27 900
Waterboy - Making Sense Of My Son's…
Glynis Horning Paperback R320 R295 Discovery Miles 2 950
The Luxury Market in Brazil - Market…
C. Diniz Hardcover R2,094 R1,787 Discovery Miles 17 870
At the Place of the Lobsters and Crabs…
William A. Haviland Hardcover R547 R507 Discovery Miles 5 070
African Artificial Intelligence…
Mark Nasila Paperback R350 R312 Discovery Miles 3 120
Red States - Indigeneity, Settler…
Gina Caison Hardcover R1,541 Discovery Miles 15 410
Legacide - Why Legacy Thinking Is The…
Richard Mulholland Paperback  (1)
R248 Discovery Miles 2 480
Commercial Distribution in Europe…
John Dawson Hardcover R1,365 Discovery Miles 13 650
# Convict Conversation - Criminal…
Charles Irving Ellis Hardcover R685 Discovery Miles 6 850
100 Mandela Moments
Kate Sidley Paperback R260 R232 Discovery Miles 2 320

 

Partners